Robert Knoerl1, Ellen M L Smith2, Amy Han3, Allison Doe4, Katelyn Scott5, Donna L Berry6. 1. Post-Doctoral Research Fellow, Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana Farber Cancer Institute, 450 Brookline Avenue, LW 517, Boston, MA 02215, USA. Electronic address: robert_knoerl@dfci.harvard.edu. 2. School of Nursing, University of Michigan, 400 N. Ingalls, Ann Arbor, MI 48109, USA. Electronic address: ellenls@umich.edu. 3. Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana Farber Cancer Institute, 450 Brookline Avenue, LG 1B, Boston, MA 02215, USA. Electronic address: amy_han@dfci.harvard.edu. 4. Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana Farber Cancer Institute, 450 Brookline Avenue, LW 517, Boston, MA 02215, USA. 5. Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana Farber Cancer Institute, 450 Brookline Avenue, LW 517, Boston, MA 02215, USA. Electronic address: adoe@mgh.harvard.edu. 6. Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, 450 Brookline Avenue, LW 518, Boston, MA 02215, USA. Electronic address: Donna_Berry@dfci.harvard.edu.
Abstract
OBJECTIVE: To describe the frequency and characteristics of chemotherapy-induced peripheral neuropathy (CIPN) assessment and management communication approaches between patients receiving neurotoxic chemotherapy and clinicians. METHODS: The data used in this analysis originated from a randomized controlled trial in which adults with cancer self-reported treatment-related symptoms using web-based symptom assessment technology. Three-to-six weeks after study initiation, each participant's outpatient visit was audio-recorded. Audio recordings and associated clinician notes for 159 participants who receivedplatinum and/or taxane-based chemotherapy were coded for the presence of several CIPN assessment and management communication characteristics. RESULTS: Participants received low cumulative neurotoxic chemotherapy doses (75%) at the time of audio recording. CIPN was discussed and documented in 44% and 46% of participant-clinician encounters. In symptomatic participants, clinicians asked an average of 0.7 open-ended questions, appropriately managed 70% of cases, and asked upper and lower extremity CIPN questions in 25% of cases. CONCLUSIONS: Clinicians infrequently discussed and documented CIPN in participants with low CIPN severity, however appropriately managed mild CIPN. Development of interventions to translate existing recommended CIPN communication approaches into practice are required. PRACTICE IMPLICATIONS: Effective participant-clinician communication is required at each clinic visit during chemotherapy treatment to identify initial signs of CIPN and offer appropriate treatment.
RCT Entities:
OBJECTIVE: To describe the frequency and characteristics of chemotherapy-induced peripheral neuropathy (CIPN) assessment and management communication approaches between patients receiving neurotoxic chemotherapy and clinicians. METHODS: The data used in this analysis originated from a randomized controlled trial in which adults with cancer self-reported treatment-related symptoms using web-based symptom assessment technology. Three-to-six weeks after study initiation, each participant's outpatient visit was audio-recorded. Audio recordings and associated clinician notes for 159 participants who received platinum and/or taxane-based chemotherapy were coded for the presence of several CIPN assessment and management communication characteristics. RESULTS:Participants received low cumulative neurotoxic chemotherapy doses (75%) at the time of audio recording. CIPN was discussed and documented in 44% and 46% of participant-clinician encounters. In symptomatic participants, clinicians asked an average of 0.7 open-ended questions, appropriately managed 70% of cases, and asked upper and lower extremity CIPN questions in 25% of cases. CONCLUSIONS: Clinicians infrequently discussed and documented CIPN in participants with low CIPN severity, however appropriately managed mild CIPN. Development of interventions to translate existing recommended CIPN communication approaches into practice are required. PRACTICE IMPLICATIONS: Effective participant-clinician communication is required at each clinic visit during chemotherapy treatment to identify initial signs of CIPN and offer appropriate treatment.
Authors: Ellen M Lavoie Smith; Grace Campbell; Cindy Tofthagen; Lisa Kottschade; Mary L Collins; Charlene Warton; Bidisha Ghosh; David L Ronis; Gail A Mallory; Constance Visovsky Journal: Oncol Nurs Forum Date: 2014-11-01 Impact factor: 2.172
Authors: Ethan Basch; Allison M Deal; Amylou C Dueck; Howard I Scher; Mark G Kris; Clifford Hudis; Deborah Schrag Journal: JAMA Date: 2017-07-11 Impact factor: 56.272
Authors: T J Postma; N K Aaronson; J J Heimans; M J Muller; J G Hildebrand; J Y Delattre; K Hoang-Xuan; M Lantéri-Minet; R Grant; R Huddart; C Moynihan; J Maher; R Lucey Journal: Eur J Cancer Date: 2005-04-14 Impact factor: 9.162
Authors: Hannah C Timmins; Tiffany Li; Terry Trinh; Matthew C Kiernan; Michelle Harrison; Frances Boyle; Michael Friedlander; David Goldstein; Susanna B Park Journal: Oncologist Date: 2021-02-10
Authors: Alice Yu; Deborah Street; Rosalie Viney; Stephen Goodall; Alison Pearce; Philip Haywood; Marion Haas; Eva Battaglini; David Goldstein; Hannah Timmins; Susanna B Park Journal: Support Care Cancer Date: 2021-04-22 Impact factor: 3.603
Authors: Allison B Wang; Stephen N Housley; Ann Marie Flores; Sheetal M Kircher; Eric J Perreault; Timothy C Cope Journal: J Neuroeng Rehabil Date: 2021-01-25 Impact factor: 4.262
Authors: Ciao-Sin Chen; Judith Kim; Noemi Garg; Harsha Guntupalli; Reshma Jagsi; Jennifer J Griggs; Michael Sabel; Michael P Dorsch; Brian C Callaghan; Daniel L Hertz Journal: JMIR Mhealth Uhealth Date: 2021-07-05 Impact factor: 4.947
Authors: Daniel L Hertz; Travis J Dockter; Daniel V Satele; Charles L Loprinzi; Jennifer Le-Rademacher Journal: Support Care Cancer Date: 2021-06-27 Impact factor: 3.603